Boan Biotech Grants AstraZeneca Exclusive Rights to Promote Boyounuo(R) (Bevacizumab Injection) in Specific County Markets of China
SHANGHAI, May 26, 2021 /PRNewswire/ -- Luye Pharma Group announced today that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drugBoyounuo® (Bevacizumab Injection), under which the former will grant to the latte...
Luye Pharma Continues to Deliver Strong Growth in 2019
SHANGHAI, March 27, 2020 /PRNewswire/ -- Luye Pharma Group (02186.HK) reported its financial results for 2019 onMarch 27, 2020. According to the results, the company has achieved a total revenue ofRMB 6.358 billion, up 22.9% year-on-year. EBITDA wasRMB 2.488 billion, up 26.9% year-on-year; and n...
Luye Pharma First Half of 2019 Results: Strong Revenue Growth and Substantial Development of R&D Product Pipelines
SHANGHAI, Aug. 29, 2019 /PRNewswire/ -- Luye Pharma Group (02186.HK) released its financial results for the first half of 2019 onAugust 28. The results show the company has achieved a revenue ofRMB 3.131 billion, up 42.1% year-on-year; EBITDA reachedRMB 1.263 billion, up 44.1% year-on-year, while...
Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As
HONG KONG, Aug. 29, 2018 /PRNewswire/ -- Luye Pharma Group (02186.HK) released its financial results for the first half of 2018 onAugust 26, with the financial report showing the company has maintained strong business performance and double-digit growth in the sale of its established products - s...
Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets
SHANGHAI, June 7, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline. On May 7, ...
Luye Pharma: A Healthy Thirty Percent Annual Growth Rate, with Competitive Product Pipelines across Different Therapeutic Areas
HONG KONG, March 29, 2018 /PRNewswire/ -- One of China's leading pharmaceutical companies, Luye Pharma (02186. HK), released its annual results onMarch 26, 2018 . The financial report shows that the company enjoyed strong growth last year, both in its domestic and international business, and that ...
Luye Pharma Announces the Completion of Acquisition of Acino's Transdermal Drug Delivery Systems Business
HONG KONG, Dec. 1, 2016 /PRNewswire/ -- Luye Pharma Group Ltd. (2186.HK) is pleased to announce the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino. The acquired business is a global leader in niche transdermal markets and will great...
